BMRN Stock Analysis: Buy, Sell, or Hold?
BMRN - BioMarin Pharmaceuticals Inc
$59.12
-0.85 (-1.42%)
▼
5d:
+0.22%
30d:
+2.09%
90d:
+5.01%
BUY
MODERATE Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 03, 2026
22d
Smart Money Accumulation
None View Scanner →
Strength: 5.1/10
Get Alerted When BMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BMRN shows positive signals but monitor for confirmation. Market pricing in 0.9% decline. Moderate conviction.
💡 BUY OPPORTUNITY: BMRN shows positive signals but monitor for confirmation. Market pricing in 0.9% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$118.17
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$73.37
19.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BMRN is currently trading at $59.12, which is considered extended relative to its 30-day fair value range of $55.17 to $58.73. The stock's valuation (Forward PE: 9.2) is in line with its historical norms (9.4). Remarkably, the market is currently pricing in an annual earnings decline of 0.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BMRN is in a uptrend. The price is approaching resistance at $60.67. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BMRN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $87.69 (+48.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BMRN is in a uptrend. The price is approaching resistance at $60.67. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BMRN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $87.69 (+48.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$55.17 -
$58.73
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 48.3% below Wall St target ($87.69)
Trading Range Analysis
30-Day Trading Range
$55.17 -
$58.73
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$56.43
Resistance Level
$60.67
Current Trend
Uptrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.16
Wall Street Target
$87.69
(+48.3%)
Revenue Growth (YoY)
2.8%
Earnings Growth (YoY)
-43.1%
Profit Margin
8.3%
Valuation Discount vs History
-0.9% cheaper
PE vs Historical
9.2 vs 9.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.9%
(market-implied from PE analysis)
1-Year Target
$58.59
(-1%)
2-Year Target
$58.06
(-2%)
3-Year Target
$57.54
(-3%)
3-Yr Target (if PE normalizes)
(PE: 9→9)
$59.06
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 30.7%)
$313.85
(+431%)
Base:
(SPY PE: 9.2, Growth: 30.7%)
$131.97
(+123%)
Bear:
(PE: 7.8, Growth: 30.7%)
$112.18
(+90%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (43x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 42.84 | Current EPS (TTM): $1.40
Bull Case
$131.93
(+123%)
Analyst growth 100.0%, PE expands to 47.1
Base Case
$119.94
(+103%)
Market implied 100.0%, PE stable at 42.8
Bear Case
$40.78
(-31%)
Severe decline -20.0%, PE contracts to 36.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.2 to 9.4
Stabilization Target:
$60.68
(+2.6%)
PE Expansion Potential:
+2.6%
Share & Embed Analysis
Last updated: July 11, 2026 4:07 AM ET
Data refreshes hourly during market hours. Next update: 5:07 AM
Data refreshes hourly during market hours. Next update: 5:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles Greg Guyer
SELL
16486 shares
2026-03-11
Gregory R Friberg
SELL
6326 shares
2026-02-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 55 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 52 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 60 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 45 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
Advanced BMRN Option Strategies
Professional options setups generated by AI based on today's BMRN price and gamma walls.
